FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2285-2293 June 2, 2005 Number 22 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The management of warfarin therapy is complicated by a wide variation among patients in drug response. Variants in the gene encoding vitamin K epoxide reductase complex 1 (VKORC1) may affect the response to warfarin.

Methods We conducted a retrospective study of European-American patients receiving long-term warfarin maintenance therapy. Multiple linear-regression analysis was used to determine the effect of VKORC1 haplotypes on the warfarin dose. We determined VKORC1 haplotype frequencies in African-American, European-American, and Asian-American populations and VKORC1 messenger RNA (mRNA) expression in human liver samples.

Results We identified 10 common noncoding VKORC1 single-nucleotide polymorphisms and inferred five major haplotypes. We identified a low-dose haplotype group (A) and a high-dose haplotype group (B). The mean (±SE) maintenance dose of warfarin differed significantly among the three haplotype group combinations, at 2.7±0.2 mg per day for A/A, 4.9±0.2 mg per day for A/B, and 6.2±0.3 mg per day for B/B (P<0.001). VKORC1 haplotype groups A and B explained approximately 25 percent of the variance in dose. Asian Americans had a higher proportion of group A haplotypes and African Americans a higher proportion of group B haplotypes. VKORC1 mRNA levels varied according to the haplotype combination.

Conclusions VKORC1 haplotypes can be used to stratify patients into low-, intermediate-, and high-dose warfarin groups and may explain differences in dose requirements among patients of different ancestries. The molecular mechanism of this warfarin dose response appears to be regulated at the transcriptional level.

Source Information

From the Departments of Genome Sciences (M.J.R., D.A.N.), Epidemiology (A.P.R.), Pharmacy (D.K.B., D.L.V.), Pharmaceutics (K.E.T.), and Medicinal Chemistry (A.E.R.), University of Washington, Seattle; and the Departments of Medicine (B.F.G., C.S.E., H.L.M.) and Pathology and Immunology (C.S.E.), Washington University, St. Louis.

Address reprint requests to Dr. Rieder at the Department of Genome Sciences, University of Washington, Box 357730, Seattle, WA 98195, or at mrieder{at}u.washington.edu.

Full Text of this Article

This article has been cited by other articles:

• Caldwell, M. D., Awad, T., Johnson, J. A., Gage, B. F., Falkowski, M., Gardina, P., Hubbard, J., Turpaz, Y., Langaee, T. Y., Eby, C., King, C. R., Brower, A., Schmelzer, J. R., Glurich, I., Vidaillet, H. J., Yale, S. H., Qi Zhang, K., Berg, R. L., Burmester, J. K. (2008). CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106-4112 [Abstract] [Full Text]  
• LOUTRADIS, D., VLISMAS, A., DRAKAKIS, P., ANTSAKLIS, A. (2008). Pharmacogenetics in Ovarian Stimulation--Current Concepts. Ann. N. Y. Acad. Sci. 1127: 10-19 [Abstract] [Full Text]  
• Teichert, M., Visser, L.E., van Schaik, R.H.N., Hofman, A., Uitterlinden, A.G., De Smet, P.A.G. M., Witteman, J.C.M., Stricker, B.H.Ch. (2008). Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification: The Rotterdam Study. Arterioscler. Thromb. Vasc. Bio. 28: 771-776 [Abstract] [Full Text]  
• Vlad, M. O., Dan Corlan, A., Moran, F., Oefner, P., Ross, J. (2008). Incremental parameter evaluation from incomplete data with application to the population pharmacology of anticoagulants. Proc. Natl. Acad. Sci. USA 105: 4627-4632 [Abstract] [Full Text]  
• Schwarz, U. I., Ritchie, M. D., Bradford, Y., Li, C., Dudek, S. M., Frye-Anderson, A., Kim, R. B., Roden, D. M., Stein, C. M. (2008). Genetic Determinants of Response to Warfarin during Initial Anticoagulation. NEJM 358: 999-1008 [Abstract] [Full Text]  
• Shurin, S. B., Nabel, E. G. (2008). Pharmacogenomics -- Ready for Prime Time?. NEJM 358: 1061-1063 [Full Text]  
• Williams, S., Wynn, G., Cozza, K., Sandson, N. B. (2007). Cardiovascular Medications. Psychosomatics 48: 537-547 [Full Text]  
• Anderson, J. L., Horne, B. D., Stevens, S. M., Grove, A. S., Barton, S., Nicholas, Z. P., Kahn, S. F.S., May, H. T., Samuelson, K. M., Muhlestein, J. B., Carlquist, J. F., for the Couma-Gen Investigators, (2007). Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation. Circulation 116: 2563-2570 [Abstract] [Full Text]  
• Millican, E. A., Lenzini, P. A., Milligan, P. E., Grosso, L., Eby, C., Deych, E., Grice, G., Clohisy, J. C., Barrack, R. L., Burnett, R. S. J., Voora, D., Gatchel, S., Tiemeier, A., Gage, B. F. (2007). Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110: 1511-1515 [Abstract] [Full Text]  
• Krynetskiy, E., McDonnell, P. (2007). Building Individualized Medicine: Prevention of Adverse Reactions to Warfarin Therapy. J. Pharmacol. Exp. Ther. 322: 427-434 [Abstract] [Full Text]  
• Shen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., Chen, W. (2007). Racial/Ethnic Differences in the Risk of Intracranial Hemorrhage Among Patients With Atrial Fibrillation. J Am Coll Cardiol 50: 309-315 [Abstract] [Full Text]  
• Falk, R. H. (2007). Ethnic Disparity in Intracranial Hemorrhage Among Anticoagulated Patients With Atrial Fibrillation: An Answer in Search of a Question?. J Am Coll Cardiol 50: 316-318 [Full Text]  
• Zhu, Y., Shennan, M., Reynolds, K. K., Johnson, N. A., Herrnberger, M. R., Valdes, R. Jr, Linder, M. W. (2007). Estimation of Warfarin Maintenance Dose Based on VKORC1 (-1639 G>A) and CYP2C9 Genotypes. Clin. Chem. 53: 1199-1205 [Abstract] [Full Text]  
• Nishioka, J., Goodin, S. (2007). Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival. J Oncol Pharm Pract 13: 85-97 [Abstract]  
• Momary, K. M. (2007). Cardiovascular Pharmacogenomics. Journal of Pharmacy Practice 20: 265-276 [Abstract]  
• Loebstein, R., Dvoskin, I., Halkin, H., Vecsler, M., Lubetsky, A., Rechavi, G., Amariglio, N., Cohen, Y., Ken-Dror, G., Almog, S., Gak, E. (2007). A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109: 2477-2480 [Abstract] [Full Text]  
• Caldwell, M. D., Berg, R. L., Zhang, K. Q., Glurich, I., Schmelzer, J. R., Yale, S. H., Vidaillet, H. J., Burmester, J. K. (2007). Evaluation of Genetic Factors for Warfarin Dose Prediction. Clin Med Res 5: 8-16 [Abstract] [Full Text]  
• Kim, Y. M., Yoo, S. H., Kang, R. Y., Kim, M. J., Bae, Y. Y., Lee, Y. K., Jeon, S. J., Chon, K. J., Shin, S. M., Kim, S. G., Park, K. H., Son, I. J. (2007). Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm 64: 166-175 [Abstract] [Full Text]  
• Crawford, D. C., Sanders, C. L., Qin, X., Smith, J. D., Shephard, C., Wong, M., Witrak, L., Rieder, M. J., Nickerson, D. A. (2006). Genetic Variation Is Associated With C-Reactive Protein Levels in the Third National Health and Nutrition Examination Survey. Circulation 114: 2458-2465 [Abstract] [Full Text]  
• Roden, D. M., Altman, R. B., Benowitz, N. L., Flockhart, D. A., Giacomini, K. M., Johnson, J. A., Krauss, R. M., McLeod, H. L., Ratain, M. J., Relling, M. V., Ring, H. Z., Shuldiner, A. R., Weinshilboum, R. M., Weiss, S. T., for the Pharmacogenetics Research Network, (2006). Pharmacogenomics: Challenges and Opportunities.. ANN INTERN MED 145: 749-757 [Abstract] [Full Text]  
• Barnes, M. R. (2006). Navigating the HapMap. Brief Bioinform 7: 211-224 [Abstract] [Full Text]  
• Gardiner, S. J., Begg, E. J. (2006). Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacol. Rev. 58: 521-590 [Abstract] [Full Text]  
• Li, T, Lange, L A, Li, X, Susswein, L, Bryant, B, Malone, R, Lange, E M, Huang, T-Y, Stafford, D W, Evans, J P (2006). Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J. Med. Genet. 43: 740-744 [Abstract] [Full Text]  
• Rettie, A. E., Tai, G. (2006). The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine. Mol. Interv. 6: 223-227 [Abstract] [Full Text]  
• Piazza, G., Goldhaber, S. Z. (2006). Acute Pulmonary Embolism: Part II: Treatment and Prophylaxis. Circulation 114: e42-e47 [Full Text]  
• Frith, M. C., Ponjavic, J., Fredman, D., Kai, C., Kawai, J., Carninci, P., Hayshizaki, Y., Sandelin, A. (2006). Evolutionary turnover of mammalian transcription start sites. Genome Res. 16: 713-722 [Abstract] [Full Text]  
• Eliasson, E. (2006). Ethnicity and adverse drug reactions.. BMJ 332: 1163-1164 [Full Text]  
• Marsh, S., McLeod, H. L. (2006). Pharmacogenomics: from bedside to clinical practice.. Hum Mol Genet 15: R89-R93 [Abstract] [Full Text]  
• Stewart, E. A., Morton, C. C. (2006). The genetics of uterine leiomyomata: what clinicians need to know.. Obstet Gynecol 107: 917-921 [Abstract] [Full Text]  
• Birman-Deych, E., Radford, M. J., Nilasena, D. S., Gage, B. F. (2006). Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation. Stroke 37: 1070-1074 [Abstract] [Full Text]  
• Wang, Y., Zhang, W., Zhang, Y., Yang, Y., Sun, L., Hu, S., Chen, J., Zhang, C., Zheng, Y., Zhen, Y., Sun, K., Fu, C., Yang, T., Wang, J., Sun, J., Wu, H., Glasgow, W. C., Hui, R. (2006). VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection). Circulation 113: 1615-1621 [Abstract] [Full Text]  
• Sabatine, M. S., Seidman, J. G., Seidman, C. E. (2006). Cardiovascular Genomics. Circulation 113: e450-e455 [Full Text]  
• Gage, B. F., Birman-Deych, E., Radford, M. J., Nilasena, D. S., Binder, E. F. (2006). Risk of Osteoporotic Fracture in Elderly Patients Taking Warfarin: Results From the National Registry of Atrial Fibrillation 2. Arch Intern Med 166: 241-246 [Abstract] [Full Text]  
• Rahimtoola, S. H. (2006). The Year in Valvular Heart Disease. J Am Coll Cardiol 47: 427-439 [Full Text]  
• Gage, B. F. (2006). Pharmacogenetics-Based Coumarin Therapy. ASH Education Book 2006: 467-473 [Abstract] [Full Text]  
• Oldenburg, J. (2005). VKORC1: the little big protein. Blood 106: 3683-3684 [Full Text]  
• Ginsburg, G. S., Konstance, R. P., Allsbrook, J. S., Schulman, K. A. (2005). Implications of Pharmacogenomics for Drug Development and Clinical Practice. Arch Intern Med 165: 2331-2336 [Abstract] [Full Text]  
• Carlson, C. S., Thomas, D. J., Eberle, M. A., Swanson, J. E., Livingston, R. J., Rieder, M. J., Nickerson, D. A. (2005). Genomic regions exhibiting positive selection identified from dense genotype data. Genome Res. 15: 1553-1565 [Abstract] [Full Text]  
• Lee, C. R. (2005). Warfarin Initiation and the Potential Role of Genomic-Guided Dosing. Clin Med Res 3: 205-206 [Full Text]  
• Guttmacher, A. E., Collins, F. S. (2005). Realizing the Promise of Genomics in Biomedical Research. JAMA 294: 1399-1402 [Full Text]  
• (2005). Genetic Variation in Warfarin-Dosing Needs. Journal Watch Cardiology 2005: 1-1 [Full Text]  
• Martyn, C. (2005). What's new in the other general journals. BMJ 330: 1351-1351 [Full Text]